A New B7:CD28 Family Checkpoint Target for Cancer Immunotherapy: HHLA2.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 25869386.
- Also identified by DOI 10.1158/1078-0432.CCR-14-2658 and PMC identifier 4433776.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
HHLA2 is a newly identified B7 family member that modulates T-cell functions through interaction with TMIGD2 and possibly a second receptor, with coinhibition in two studies and costimulation in one study. HHLA2 is expressed on a variety of human cancers, and its coinhibitory function makes it a candidate for cancer immunotherapy.
Medical subject headings
- Immunoglobulins
- Triple Negative Breast Neoplasms